Advances on receptor tyrosine kinase inhibitors taking c-Met as anti-tumor target
10.11665/j.issn.1000-5048.20150102
- VernacularTitle:以c-Met为肿瘤治疗靶点的受体酪氨酸激酶抑制剂的研究进展
- Author:
Yuan ZHANG
1
;
Yulan CHENG
;
Jinpei ZHOU
;
Huibin ZHANG
Author Information
1. 中国药科大学药物化学教研室
- Publication Type:Journal Article
- Keywords:
receptor tyrosine kinase;
c-Met;
cross-talk;
drug resistance;
c-Met inhibitors;
anti-tumor target;
cabozantinib;
crizotinib
- From:
Journal of China Pharmaceutical University
2015;46(1):16-27
- CountryChina
- Language:Chinese
-
Abstract:
c-Met receptor tyrosine kinase plays an important role in signaling pathways including cell proliferation, metabolism as well as tumorigenic growth, migration and angiogenesis. c-Met has emerged as an attractive target for cancer therapy. Moreover, the interactive cross-talk between c-Met signaling and several other signaling pathways underlies a key effect for resistance of anti-cancer drugs. Thus, multi-target inhibitors become a new approach to cancer therapy. This paper introduces the c-Met signaling pathway and the resistance of kinase inhibitors caused by the cross-talk between c-Met and other membrane receptors and then will reviews the progress of single-target and multi-target c-Met inhibitors.
